Semax represents a synthetic heptapeptide engineered from the adrenocorticotropic hormone (ACTH) N-terminal fragment, specifically utilizing the ACTH(4–7) sequence with an additional Pro-Gly-Pro tripeptide extension. Developed within Russian scientific institutions throughout the 1980s and 1990s, this compound has garnered substantial global preclinical attention for its modulation of neurotrophic signaling, especially pathways mediated by brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). Among short synthetic peptides explored in central nervous system (CNS) research frameworks, Semax maintains prominence as researchers advance neuropeptide biology investigations in 2026.
Laboratory studies examining Semax have addressed neurotrophin expression patterns, neuroprotective pathways, cognitive function modeling, and cerebrovascular mechanisms. The peptide's compact molecular architecture, enhanced metabolic stability relative to native ACTH sequences, and demonstrated intranasal bioavailab